Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) subsidiary Shandong Shengdi Pharmaceutical obtained the approval of China's drug administrator to conduct clinical trials for HRS-7535 tablets.
HRS-7535 is indicated for the treatment of hypertension combined with overweight or obesity., according to a Tuesday filing with the Shanghai bourse.
Shares of the drugmaker were up 2% in recent trade on the Shanghai and Hong Kong bourses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments